18F-氟妥昔洛司他PET/CT与68Ga-PSMA-11及99mTc-MAG3显像评估分肾功能的比较
该研究回顾性分析302例接受PSMA放射性配体治疗前的转移性去势抵抗性前列腺癌患者,分别用18F-F-flotufolastat或68Ga-Ga-PSMA-11 PET/CT计算分肾功能,并与99mTc-Tc-MAG3显像对照。两种PET示踪剂的分肾功能均与MAG3显像强相关,18F-F-flotufolastat的一致性和诊断准确性略优。
要点
- PSMA-PET/CT可可靠估算分肾功能,18F-F-flotufolastat与MAG3一致性略优于68Ga-PSMA-11。
- 18F-F-flotufolastat识别MAG3-SRF≤25%的AUC达0.997,68Ga-PSMA-11为0.942。
- 基于PET的累积指数与eGFR无显著关联,两种示踪剂均如此。
核心结论
- PSMA-PET/CT能可靠估算分肾功能,18F-F-flotufolastat与99mTc-Tc-MAG3显像的一致性略优于68Ga-PSMA-11。
- 未来可能免去额外肾显像评估分肾功能,简化流程并减轻患者负担。
研究设计与样本
- 回顾性分析302例转移性去势抵抗性前列腺癌患者,PSMA放射性配体治疗前接受PSMA-PET/CT和99mTc-Tc-MAG3显像。
- 18F-F-flotufolastat组221例,68Ga-Ga-PSMA-11组81例;PET-SRF由平均标准化摄取值和CT肾体积计算,MAG3-SRF用标准积分分析。
- 采用Pearson相关和Bland-Altman分析侧别SRF一致性,ROC分析检测肾功能受损(SRF≤25%和≤40%),并探索性分析PET累积指数与eGFR关系。
主要发现
- PET-SRF与MAG3-SRF强相关:18F-F-flotufolastat r=0.88,68Ga-Ga-PSMA-11 r=0.85,均p<0.0001。
- Bland-Altman分析示18F-F-flotufolastat平均偏差-0.56%(一致性界限-11.88%至+10.75%),68Ga-Ga-PSMA-11平均偏差-1.18%(-15.3%至+12.95%)。
- 18F-F-flotufolastat有92%的值在±10%内,68Ga-Ga-PSMA-11为83%。
- 识别MAG3-SRF≤25%的AUC:18F-F-flotufolastat为0.997,68Ga-Ga-PSMA-11为0.942。
- 累积指数与eGFR无显著关联:18F-F-flotufolastat Spearman ρ=0.056(p=0.414),68Ga-Ga-PSMA-11 ρ=−0.071(p=0.536)。
关键数值与推荐
- 分肾功能受损的ROC分析阈值定义为MAG3-SRF≤25%和≤40%。
- PET-SRF计算采用平均标准化摄取值和CT肾体积;MAG3-SRF采用标准积分分析。
- 一致性评估采用Pearson相关和Bland-Altman分析,诊断性能采用ROC曲线分析。
临床怎么用
- 在PSMA放射性配体治疗前,可利用PSMA-PET/CT同时评估分肾功能,可能减少额外99mTc-Tc-MAG3肾显像的需要。
- 18F-F-flotufolastat在分肾功能评估中与MAG3显像一致性较高,或可优先用于简化流程。
局限性
- 回顾性研究设计,18F-F-flotufolastat组与68Ga-Ga-PSMA-11组样本量不均衡(221例对81例)。
- 累积指数与eGFR的关联为探索性、示踪剂特异性分析,未观察到显著关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Physiological prostate-specific membrane antigen (PSMA) expression in renal proximal tubules results in radiopharmaceutical uptake in PSMA-PET, suggesting the potential to assess renal function. To evaluate split renal function derived from [18F]F-flotufolastat ([18F]F-rhPSMA-7.3) PET/CT and to systematically compare its performance with [68Ga]Ga-PSMA-11 PET/CT and the reference standard [99mTc]Tc-MAG3 scintigraphy, we retrospectively analyzed 302 patients with metastatic castration-resistant prostate cancer undergoing PSMA-PET/CT using either [18F]F-flotufolastat (n = 221) or [68Ga]Ga-PSMA-11 (n = 81), along with [99mTc]Tc-MAG3 scintigraphy, prior to PSMA radioligand therapy. SRF was calculated from PSMA-PET/CT using mean standardized uptake values and CT-derived renal volumes. SRF was calculated from [99mTc]Tc-MAG3 using standard integral analysis. SRF derived from PSMA-PET/CT ([18F]F-flotufolastat and [68Ga]Ga-PSMA-11) was correlated with split renal function obtained from [99mTc]Tc-MAG3 scintigraphy on a side-specific basis using Pearson correlation and Bland–Altman analysis. Receiver operating characteristic (ROC) analyses were performed to evaluate diagnostic performance for detecting impaired renal function (SRF ≤ 25% and ≤ 40%). A PET-based accumulation index (ACI) was explored in relation to estimated glomerular filtration rate (eGFR) in an exploratory, tracer-specific analysis. RESULTS: Strong correlations were found between PET-SRF and [99mTc]Tc-MAG3-SRF (r = 0.88 for [18F]F-flotufolastat, r = 0.85 for [68Ga]Ga-PSMA-11; both p < 0.0001). Bland–Altman analysis showed a smaller mean bias and narrower limits of agreement for [18F]F-flotufolastat (-0.56%; -11.88% to + 10.75%) compared with [68Ga]Ga-PSMA-11 (-1.18%; -15.3% to + 12.95%), with 92% versus 83% of values within ± 10%, respectively. ROC analysis confirmed excellent accuracy for identifying [99mTc]Tc-MAG3-SRF ≤ 25% (area under the curve [AUC] = 0.997 for [18F]F-flotufolastat; AUC = 0.942 for [68Ga]Ga-PSMA-11). No significant association was observed between ACI and eGFR for either radiopharmaceutical ([18F]F-flotufolastat: Spearman’s ρ = 0.056, p = 0.414; [68Ga]Ga-PSMA-11: Spearman’s ρ = − 0.071, p = 0.536). CONCLUSION: PSMA-PET/CT provides reliable estimates of SRF, with [18F]F-flotufolastat showing slightly superior agreement with [99mTc]Tc-MAG3 scintigraphy. This may potentially eliminate the need for additional renal scintigraphy for SRF assessment in the future and may simplify workflows and reduce patient burden.
引用
- Gammel MCM, Olufs C, Hansen K, et al. Estimation of split renal function using [18F]-flotufolastat PET/CT compared with [68Ga]-PSMA-11 and [99mTc]-MAG3 scintigraphy. EJNMMI Res. 2026. PMID: 41634508. doi:10.1186/s13550-026-01385-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。